Boone Capital Trims Abeona Therapeutics Stake

Hedge fund reduces position in biopharmaceutical company by nearly 60%

Mar. 15, 2026 at 8:58am

Got story updates? Submit your updates here. ›

Boone Capital Management LLC decreased its holdings in shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) by 59.9% during the third quarter, according to a recent SEC filing. The fund now owns 502,854 shares of the biopharmaceutical company's stock, down from 1.25 million shares previously.

Why it matters

Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for rare diseases. Institutional investors like Boone Capital closely monitor the company's progress and financial performance, and changes in their holdings can signal broader market sentiment.

The details

According to the filing, Boone Capital Management sold 751,804 shares of Abeona Therapeutics during the third quarter. The hedge fund now owns approximately 0.93% of the company's outstanding shares, valued at $2.66 million as of the most recent SEC report.

  • Boone Capital Management decreased its Abeona Therapeutics holdings during the third quarter of 2026.

The players

Boone Capital Management LLC

An Iowa-based hedge fund that previously held a significant stake in the biopharmaceutical company Abeona Therapeutics.

Abeona Therapeutics Inc.

A clinical-stage biopharmaceutical company focused on developing gene and cell therapies for rare diseases.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Boone Capital's Abeona Therapeutics position suggests the hedge fund may have concerns about the company's near-term prospects, though the reasons behind the move are not entirely clear. Investors will likely continue to monitor Abeona's progress and any changes in institutional ownership as the company advances its pipeline of experimental therapies.